StockNews.AI
NVS
StockNews.AI
159 days

Novartis Pharmaceuticals and Folia Health Partner on Innovative App-Based Study to Assess Real-World Experience of IgA Nephropathy

1. Novartis collaborates with Folia Health on IgA nephropathy study. 2. Study focuses on real-world evidence via patient-reported outcomes. 3. First initiative capturing at-home insights on IgAN management. 4. Participants engage remotely, providing valuable treatment impact data. 5. Potential for improved understanding of IgAN treatment effectiveness.

6m saved
Insight
Article

FAQ

Why Bullish?

This collaboration can enhance NVS's reputation and market position in nephrology. Similar historical partnerships in healthcare have positively influenced stock prices.

How important is it?

The collaboration indicates a strategic focus on patient-centric care, enhancing NVS's future business potential.

Why Long Term?

Insights gathered from this initiative could lead to new therapies, improving NVS's product pipeline over time.

Related Companies

RMDABBVAMGN
BOSTON, March 13, 2025 (GLOBE NEWSWIRE) -- Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initiative supporting individuals with IgA nephropathy. This ground-breaking study will leverage Folia’s cutting-edge technology platform, allowing participants to track changes and quality of life impacts based on the symptoms most relevant to them- whether commonly associated with IgAN or not- alongside their individual treatment plan during an initial six-month observational period. By enabling participants to self-select and define what’s most relevant to them, rather than relying solely on pre-specified patient-reported outcomes (PROs), this approach provides a comprehensive and nuanced understanding of the lived experiences of IgAN. This study is the first real-world data program designed to capture the at-home experiences of individuals and caregivers managing IgAN. Developed in collaboration with IgAN patients themselves, it directly measures patient-defined burden and evaluates the impact of various treatments on quality of life. As new therapies for IgAN become available, these insights will provide a timely and valuable understanding of real-world day-to-day experiences and treatment outcomes in this population. Through the Folia platform, IgAN patients and caregivers can actively engage with their own study observations, gaining deeper insights into their symptom burden, treatment effects, and acute health events. The Folia app can generate tracking summary reports, allowing users to easily visualize their changes over time- such as symptom severity trends, frequency of flare-ups, and treatment responses. Folia can also overlay treatment usage with symptom severity and patients can export visual reports to share with their care teams. This study is entirely remote, eliminating the need for clinic visits while still enabling participants to use their tracked data during medical appointments, ensuring that real-world insights can directly inform their care. “The point of Folia is to provide a tool to help people with chronic conditions take more control over their care, and understand how their treatment plan is working for them. We're excited to bring these capabilities to kidney disease with this IgAN program, and look forward to the insights on treatment effectiveness and living with IgAN that our participants share with our research teams," said Nell Meosky Luo, the CEO & Founder of Folia Health. “Advancing IgAN research requires more precise, real-world data captured directly from patients over time. This program enables the collection of granular, home-reported outcomes for the first time in this population, offering a richer, more accurate view of disease progression and treatment impact in everyday life,” said Briana Ndife, Director, HEOR, Nephrology at Novartis Pharmaceuticals. About Folia Health: Folia Health is the founder of home-reported outcomes (HROs), the next generation of patient health data that transforms lived experiences outside the clinic into valuable insights for better research and care. Through an innovative platform backed by expert analysis and support from a compassionate team, we help life science partners develop effective therapies with demonstrated, real-world value for complex, chronic conditions. Folia's wealth of longitudinal data and proprietary analytics play a vital role in establishing a home-centered, data-driven healthcare ecosystem. To explore the transformative potential of patient and caregiver knowledge, visit www.foliahealth.com. About Novartis Pharmaceuticals: Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Folia Health Contact:Connie Zhang+1 617-306-1282connie@foliahealth.com Novartis Contact:Briana Ndifebriana.ndife@novartis.com

Related News